Vaccine Info

Sputnik V Vaccine

Authored by
Staff
Last reviewed
April 8, 2021

Sputnik V Vaccine Description

The COVID-19 vaccine Sputnik V (Gam-COVID-Vac) is an adenoviral-based vaccine against the SARS-CoV-2 coronavirus. Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.

It is a vector vaccine based on adenovirus DNA, in which the SARS-CoV-2 coronavirus gene is integrated. Adenovirus is used as a “container” to deliver the coronavirus gene to cells and start the synthesis of the new coronavirus's envelope proteins, “introducing” the immune system to a potential enemy.

The Sputnik V (Gam-COVID-Vac) vaccine reduces the time taken for the actual development of immunity to SARS-CoV-2, the virus behind the COVID-19 pandemic.

In May 2020, a state institute, the Gamaleya National Research Centre of Epidemiology and Microbiology, announced that it had developed the vaccine, which does not have any side effects. The first vaccination leads to humoral cellular immunity, and once a second vaccination is administered, memory cells are formed.

The Sputnik V vaccine was developed by the same government labs that created what is claimed as "effective against the Ebola virus, as well as a vaccine against the MERS virus.”

On February 2, 2021, The Lancet published a new study: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine, an interim analysis of a randomized controlled phase 3 trial in Russia. This peer-reviewed article concluded the phase 3 trial of Gam-COVID-Vac showed 91.6% efficacy against COVID-19 and was well tolerated in a large cohort.

On March 22, 2021, the Ulema Council confirmed 'faith does not forbid Russian Muslims from getting vaccinated with Sputnik V, after considering two components of the Covid-19 vaccine for Sharia compliance.'

The Sputnik V vaccine (Gam-COVID-Vac) (Спутник V) Accession Number: DB15848.

Sputnik V Vaccine History

On August 1, 2020, the Russian Health Minister Mikhail Murashko told reporters the 'clinical trial had been declared completed' and was then registered.

The Russian Direct Investment Fund (RDIF) was announced on August 20, 2020. The Sputnik V coronavirus vaccine candidate will be tested on 40,000 volunteers in more than 45 medical centers to confirm clinical efficacy post-approval studies.

On August 20, 2020, the Russian Direct Investment Fund (RDIF) and the Gamaleya National Research Institute of Epidemiology and Microbiology launched an information section about “Sputnik V” www.sputnikvaccine.com.

TASS reported on September 9, 2020, 'Russian Healthcare Minister Mikhail Murashko announced that Phase 3 of clinical trials of the Sputnik V vaccine against the novel coronavirus started in Russia.'

On October 27, 2020, RDIF announced it had submitted applications to the World Health Organization for an Emergency Use Listing and prequalification of the Sputnik V vaccine candidate. This news indicates the Russian Federation became one of the first countries in the world to apply to WHO for prequalification of its vaccine against the new SARS-CoV-2 coronavirus infection.

On November 24, 2020, positive results of the second interim analysis of Phase III data of the Sputnik V coronavirus vaccine were reported. The evaluation of efficacy was carried out among 18,794 volunteers on the 28th day after receiving the first injection (the 7th day after receiving the second injection) of the vaccine or placebo upon reaching the second checkpoint following the Clinical Study Protocol. Based on the analysis, the efficiency of Sputnik V was 95%.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented in a press release issued on December 11, 2020: 'AstraZeneca's decision to conduct a study using one of the two vectors of the Sputnik V vaccine is an important step towards joining forces in the fight against the pandemic. We welcome the beginning of a new phase of cooperation between vaccine manufacturers, intend to develop this partnership in the future, and look forward to starting co-production after the new vaccine has been demonstrated to be effective in clinical trials. We hope other vaccine manufacturers will also follow our example.'

On January 18, 2021, the RDIF and The National Research Center for Epidemiology and Microbiology announced an International Scientific Advisory Board on the Sputnik V vaccine. Leading scientists in virology, microbiology, genetics, and biotechnology from Argentina, Croatia, France, Germany, India, Russia, Sweden, UK, and the USA, representing top research and medical centers, have joined the Board.

Denis Logunov and colleagues reported their interim results from a phase 3 trial of the Sputnik V COVID-19 vaccine in The Lancet on February 2, 2021. The trial results show a consistent strong protective effect across all participant age groups.

RDIF was established in 2011 and provided support to facilitate partnerships, including that with Gamaleya National Research Institute of Epidemiology and Microbiology and the Central Research Institute of the Radiation, Chemical, and Biological Defense Troops.

AstraZeneca Vaccine Co-Development

The Russian Direct Investment Fund announced on February 9, 2021, that the Ministry of Health of the Republic of Azerbaijan had issued a clinical trial permit for a combined COVID-19 vaccine candidate, which includes the Sputnik V vaccine and technology co-developed by AstraZeneca and Oxford University. These clinical trials will begin in late February 2021 and plan to evaluate the combined vaccine's immunogenicity and safety over the course of six months in several countries.

QazCovid-in Vaccine Against COVID-19

The Karaganda Pharmaceutical Complex, located in Karaganda, Kazakhstan, plans to use the Sputnik V vaccine to produce the QazCovid-In Vaccine in the second quarter of 2021. This COVID-19 vaccine candidate is currently undergoing a phase 3 clinical study sponsored by Research Institute for Biological Safety Problems. This study's estimated Primary Completion Date is March 31, 2021.

Sputnik Light Vaccine

Moscow Mayor Sergei Sobyanin wrote in a blog post on February 18, 2021, 'a new vaccine candidate developed at the Institute Gamaleya is intended to eliminate the main drawback of the classic "Sputnik V" - the presence of two components administered to the patient with a difference of several weeks. Vaccination with Sputnik Light, only one visit to the polyclinic is required. Immunity will begin to form a week later and peak four weeks after vaccination. The new drug is based on the same special structures (carrier vectors) as in Sputnik V. The vaccine does not contain the coronavirus itself, which means that it will be impossible to get sick with it or infect others.'

Sputnik Light international clinical trials will be attended by 6,000 people: 3,000 each from Russia and the United Arab Emirates. The Russian part of the research will take place in Moscow at 10 city polyclinics.

The Sputnik V vaccine was created at the N.F. Gamaleya Research Center for Epidemiology and Microbiology Ministry of Health of Russia.

Sputnik V Vaccine Indication

Russian COVID-19 Vaccine candidate (Gam-COVID-Vac) is indicated to build immunity to SARS-CoV-2, the virus which causes COVID-19 disease.

Pediatric, pregnancy, and oncology vaccine efficacy data pending.

Sputnik V is available in a lyophilized (dry) form of the vaccine that significantly facilitates the logistics of its distribution in international markets due to simplified requirements for its storage temperature (+ 2 - 8 degrees Celsius).

Sputnik V Vaccine Side Effects

Offical side effect information is pending.

According to the local media source TASS, the Head of the Gamaleya Research Center for Epidemiology and Microbiology Alexander Ginzburg stated that '15% of those vaccinated report redness in the area of the vaccine shot and a slight headache that goes away within 24 hours.'

Sputnik V Vaccine Ingredients 

The active components are a modified replication-defective adenovirus of a different serotype (Serotype 26 for the first component and serotype 5 for the second), which has been modified to include the protein S-expressing gene of SARS-CoV-2. The ingredients include Tris-(hydroxymethyl)-aminomethane, Sodium chloride, Sucrose, Magnesium chloride hexahydrate, Disodium EDTA dihydrate, Polysorbate 80, Ethanol, and Water.

Interfax reported on February 12, 2021, the Sputnik V coronavirus vaccine does not contain any components prohibited by Islam, Vladimir Gushchin, head of the laboratory of mechanisms of population change of pathogenic microorganisms at the Gamaleya Center, said. Responding to a follow-up question as to whether the vaccine has any components of animal origin, he said, "Absolutely not."

Sputnik V Vaccine Cost

The cost of 1 dose of the Sputnik V vaccine for international markets will be less than $10. Sputnik V is a 2-dose vaccine. Thus, it will cost less than $20 per person.

Sputnik V Vaccine Distribution Agreements

As of March 30, 2021, the following 59 countries had authorized the Sputnik V Vaccine: Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska ( Entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Slovakia, Angola, Congo, the Republic of Djibouti, Sri Lanka, the Republic of Iraq, Kenya, the Kingdom of Morocco, Jordan, Namibia, Azerbaijan, Cameroon, the Philippines, Seychelles, Mauritius, Vietnam, Antigua and Barbuda, Mali, and the Republic of Panama.

On February 19, 2021, the Africa Vaccine Acquisition TaskTeam, set up by the African Union to acquire additional vaccine doses so that Africa can attain a target immunization of 60%, is pleased to advise that it has received an offer of 300 million Sputnik V vaccines from the Russian Federation. This includes a financing package for any member states wishing to secure this vaccine.

Sputnik V Vaccine Legal Matters

The Russian news agency TASS reported on March 22, 2021, a US company may have violated patent rights to the Sputnik V vaccine. The CEO of the Russian Direct Investment Fund, Kirill Dmitriev, commented, "One of the US companies manufacturing the vaccine violates our patents. We have notified this company and want to start a dialog. We will not claim any funds from them during the pandemic period, but we will definitely take the protection of our intellectual property rights seriously."

Sputnik V Vaccine News

April 5, 2021 - The Russian Direct Investment Fund and Panacea Biotec, one of the leading vaccine and pharmaceutical producers in India, announce cooperation to produce 100 million doses per year of the Sputnik V vaccine. Panacea Biotec has a track record of supplying more than 10 billion doses of Polio vaccines and over 150 million doses of Innovative fully liquid Vaccines to National Governments, UN Agencies, etc. Panacea Biotec’s vaccine manufacturing facilities are WHO Prequalified, pharmaceutical and sterile cytotoxic injectable facilities are USFDA approved.

April 1, 2021 - The Russian Direct Investment Fund and TopRidge Pharma (a subsidiary company of Tibet Rhodiola Pharmaceutical Holding) have agreed to cooperate on the production of over 100 million Sputnik V vaccine doses per year in China.  The parties also intend to cooperate on clinical trials of the vaccine in China. TopRidge Pharma will be able to distribute the vaccine in mainland China as well as in Hong Kong, Macao, and Taiwan, subject to all appropriate regulatory approvals.

March 29, 2021 - The Russian Direct Investment Fund and Shenzhen Yuanxing Gene-tech Co., Ltd. have agreed to cooperate on the production of over 60 million doses of the Sputnik V in China. This amount of the vaccine will be sufficient to vaccinate over 30 million people. The commercial production is due to start in May 2021.

March 25, 2021 - The Russian Direct Investment Fund (RDIF) announced the Republic of Serbia would become the first state in Southern Europe to produce the Sputnik V vaccine. The Torlak Institute of Virology, Vaccines, and Serums will begin producing the vaccine in May 2021. The Torlak Institute is a state-owned manufacturer and supplier of vaccines to medical institutions in Serbia.

March 25, 2021 - The Times of India reported Dr. Reddy’s Laboratories has submitted phase 2 and 3 study data to the Drug Controller General of India as requested and awaits final review. If approved, 100 million doses of the Sputnick V vaccine would become available in India.

March 25, 2021 - Reuters reported Ministry of Health of the Republic of Belarus confirmed the country began producing the Sputnik V vaccine. Belarus plans to produce up to 500,000 vaccine doses per month.

March 24, 2021 - According to a recent survey, 54% of respondents named Russia as the most trusted state of vaccine production. The results of the survey conducted by YouGov are based on 9,417 respondents in 9 countries.

March 22, 2021 - The Russian Direct Investment Fund (RDIF) and Virchow Biotech Private Limited (part of the Virchow Group), one of the leading manufacturers of vaccines and pharmaceuticals in India, announced an agreement to manufacture in the country annually up to 200 million doses of the Sputnik V vaccine. Completion of the technology transfer is planned for the 2nd quarter of 2021, after which the full-scale production of the Sputnik V vaccine will be launched.

March 20, 2021 - Mexico Ministry of Health released data of its vaccination program.

March 19, 2021 - Russian Direct Investment Fund and Stelis Biopharma Pvt. Ltd. announced a partnership to manufacture and supply at least 200 million doses of the Sputnik V vaccine, which will vaccinate 100 million people. The parties intend to begin deliveries of Sputnik V in the third quarter of 2021.

March 19, 2021 - The BMJ published a Feature: Covid-19: What do we know about Sputnik V and other Russian vaccines?

March 17, 2021 - The General Administration of Customs, in coordination with the Mexican Army, seized Russian Sputnik V vaccines at the Campeche International Airport, which were intended to be transferred in a private aircraft to Honduras, for which an investigation opened to determine the origin of the vaccine doses against SARS-CoV2.

March 16, 2021 - India-based Gland Pharma Ltd. announced an agreement with the Russian Direct Investment Fund to produce and supply up to 25.2 doses of the Sputnik V COVID-19 vaccine. The estimated delivery is late in 2021.

March 14, 2021 - The Philippine Food and Drug Administration stated Russia’s Gamaleya Institute has completed its documents for the Sputnik V vaccine's emergency use application (EUA) in the Philippines and was now up for evaluation, reported local media. Dr. Oscar Gutierrez Jr., the FDA’s deputy director-general for field operations, commented 'They completed their requirements only yesterday. So it is up for evaluation, and I will be part of that team. And based on the initial evaluation, they have already satisfied the certificate of GMP requirements,” he told ANC's “Dateline Philippines. “Upon review on Monday, the team will evaluate if an inspection will be needed before we grant the EUA. We are only concerned about the vaccine. The focus is not on the GMP inspection but on the proof of GMP that the manufacturer is able to produce the vaccine consistently based on the approved specification that the FDA will grant."

March 8, 2021 - Local media reported the Italian-Russian Chamber of Commerce announced the Italian-Swiss firm Adienne Pharma & Biotech signed an agreement to manufacture the Sputnik V vaccine near Milan, in Lombardy. Adrienne is an integrated biopharmaceutical group of companies based in Lugano, Switzerland.

March 4, 2021 - The European Medicines Agency announced the human medicines committee had started a rolling review of Sputnik V (Gam-COVID-Vac), a COVID-19 vaccine developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology. The applicant for this medicine is R-Pharm Germany GmbH.

March 3, 2021 - The Russian Direct Investment Fund announced the Sputnik V vaccine's approval by regulatory authorities of the Republic of Angola, the Republic of the Congo, and the Republic of Djibouti. Sputnik V has been registered under the emergency use authorization procedure. It is now approved for use in 42 countries globally, with a total population of over 1.1 billion people.

February 28, 2021 - TASS reported the Czech Republic might begin to use the Sputnik V vaccine, according to comments by Czech Prime Minister Andrej Babis. "We are working [to have the Russian vaccine as soon as possible]. The State Institute for Drug Control will consider the vaccine’s documents, and after that, the health ministry is to issue a permit for the use of the vaccine [in the Czech Republic]," he noted.

February 26, 2021 - Russian Direct Investment Fund (RDIF), JSC Generium, and RUE Belmedpreparaty, the largest pharmaceutical company in the Republic of Belarus, launch the production of the world's first registered vaccine against coronavirus Sputnik V. Denis Manturov, Minister of Industry and Trade of the Russian Federation, commented: “The joint production of the Sputnik V vaccine is an important stage in cooperation between our countries. Industrial cooperation and the development of cooperation make it possible to effectively implement such significant joint projects to protect the Republic of Belarus's population. Our countries have also reached an agreement to begin work on improving and modernizing the laboratory facilities of the Republic of Belarus. Also, the issue of creating a full-scale production of the Russian vaccine there is being worked out.” Assistance in technology transfer is provided by the Gamaleya Institute, Generium, and RDIF.

February 23, 2021 - The Russian Direct Investment Fund announced the delivery of the first batch of the Sputnik V vaccine to Mexico. The first delivery to Mexico is sufficient to vaccinate 200,000 people.

February 21, 2021 - TASS reported the Balkan country of Montenegro launched a vaccination program with the Sputnik V vaccine. The Public Health Institute of Montenegro announced the vaccine was delivered at care houses for the elderly. The total number of COVID-19 related fatalities in Montenegro since the beginning of the pandemic is 950.

February 19, 2021 - The Africa Vaccine Acquisition TaskTeam is pleased to advise that it has received an offer of 300 million Sputnik V vaccines from the Russian Federation. “The Sputnik V vaccine from the Russian Federation is now available on the AMSP for the consideration of our AU Member States,” says Dr. John Nkengasong, Director of the Africa Centres for Disease Control and Prevention. “Bilateral and private sector partnerships such as these aids our efforts to bringing the COVID-19 pandemic to an end.”

February 18, 2021 - Moscow's mayor reported specialists had developed a nasal form of "Sputnik V," which forms immunity in the nasopharynx area. This drug is not a substitute for complete vaccination, but it can be useful as an additional form of protection. All three phases of clinical trials of the drug are also planned to be carried out in Moscow.

February 18, 2021 - TASS reported Italy’s Lazzaro Spallanzani National Institute for Infectious Diseases provided its own positive evaluation of the Sputnik V vaccine's efficacy and safety against the coronavirus, which was sent to the Italian Health Ministry. 'If a vaccine is effective and safe, it should be used in Italy," the specialist added.

February 16, 2021 - South Africa’s health ministry stated that the Sputnik V COVID-19 vaccine manufacturers had submitted documentation to local medicines regulator SAHPRA for registration. SAHPRA is tasked with regulating (monitoring, evaluating, investigating, inspecting, and registering) all health products. This includes clinical trials, complementary medicines, medical devices, and in-vitro diagnostics.

February 15, 2021 - TASS reported Kazakhstan officials had registered the Sputnik V vaccine produced by the Karaganda Pharmaceutical Complex. Kazakhstan began to vaccinate its population against COVID-19 on February 1, 2021, with Russia’s Sputnik V vaccine. Starting February 15th, Kazakhstan plans to use the Sputnik V vaccine produced locally. In the second quarter of 2021, the government plans to start vaccination with the Kazakh-developed COVID-19 vaccine QazCovid-In, which is currently undergoing the third stage of clinical trials.

February 12, 2021 - Interfax reported the Sputnik V coronavirus vaccine does not contain any components prohibited by Islam, Vladimir Gushchin, head of the laboratory of mechanisms of population change of pathogenic microorganisms at the Gamaleya Center, said.

February 12, 2021 - The Russian Direct Investment Fund announced the Sputnik V vaccine's approval in Serbia, Montenegro, Saint Vincent, and the Grenadines. In total, 26 countries have already authorized the Sputnik V vaccine.

February 12, 2021 - Hungary became the first EU nation to use the Sputnik V vaccine. "Today, we are beginning to vaccinate with the Sputnik V vaccine, and this is taking place in the designated vaccination stations," Cecilia Muller, Hungary's chief medical officer, told a daily press briefing in Budapest.

February 12, 2021 - TASS reported that those vaccinated with Russia’s Sputnik V vaccine have enough antibodies to donate plasma to treat COVID-19 patients, head of the Gamaleya Research Center for Epidemiology and Microbiology Alexander Ginzburg said on Friday in an interview with the Rossiya-24 TV channel.

February 9, 2021 - The Russian Direct Investment Fund (RDIF) announced the Sputnik V vaccine registration by the Ministry of Health of Mongolia. The vaccine was approved under the emergency use authorization procedure without additional clinical trials. The EUA was obtained with assistance from RDIF's local partner Mongol Emimpex Concern LLC, the country's leading pharmaceutical company.

February 9, 2021 - The Russian Direct Investment Fund announced the Drug Regulatory Authority of Pakistan's approval to use the Sputnik V vaccine against the SARS-CoV-2 coronavirus, which causes COVID-19.

February 9, 2021 - The Russian Direct Investment Fund announced that the Ministry of Health of the Republic of Azerbaijan had issued a permit to conduct clinical trials for a combined vaccine candidate, including Sputnik V technology and the vaccine developed jointly by AstraZeneca and Oxford University. Clinical trials will begin till the end of February 2021. This clinical study will evaluate the immunogenicity and safety of the combined vaccine. The research will be carried out over the course of six months in several countries.

February 7, 2021 - The Moscow Times reported Hungarian health authorities had approved the Sputnik V vaccine.

February 6, 2021 - The Russian Direct Investment Fund announced the Sputnik V coronavirus vaccine registration in the Republic of the Union of Myanma.

February 5, 2021 - The Russian Direct Investment Fund announced the Lebanese Ministry of Health had registered the Russian Sputnik V vaccine.

February 4, 2021 - Reuters reported Paraguay signed a contract to purchase the Sputnik V vaccine with the Russian Direct Investment Fund.

February 4, 2021 - ANSA reported the Sputnik V vaccine arrived at Ben Gurion airport and transferred to the Palestinian National Authority (PNA). The Palestinian government has also purchased two million vaccine doses, the arrival of which is "expected in Palestine during late February, and they will be able to vaccinate one million people." The health minister said priority would be given to medical personnel, the elderly, and the chronically ill. The vaccinations will occur in 45 centers spread throughout the West Bank and Gaza.

February 3, 2021 - The Russian Direct Investment Fund announced Sputnik V's registration with the Federal Commission for Protection against Sanitary Risks of Mexico. Mexico became the first state in North America to register the Sputnik V vaccine and the 17th country to approve the COVID-19 vaccine.

February 2, 2021 - National Research Center for Epidemiology and Microbiology named after N.F. The Gamaleis of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund announced the publication in The Lance the results of the Phase III clinical study of the Sputnik V vaccine, confirming its high efficacy safety. An interim efficacy analysis based on data from a randomized, double-blind, placebo-controlled clinical trial of 19,866 volunteers who received both doses of the Sputnik V vaccine 21 days apart demonstrated its effectiveness against the coronavirus at 91.6%. Additionally, an efficacy analysis was performed based on the distribution of 78 confirmed cases of coronavirus detected in the placebo group (62 patients) and the vaccine group (16 patients). Sputnik V has developed a stable humoral and cellular immune response.

February 1, 2021 - Irek Ziganshin, Chairman of the Halal Standard Committee of the Muslim Spiritual Directorate of Tatarstan, said some 25 million Muslims live in Russia, and they want to make sure that the vaccines comply with Halal standards.

February 1, 2021 - The first shipment of 2,000 doses of the Russian Sputnik V COVID-19 vaccine arrived in Bosnia and Herzegovina (BiH), said Alen Seranic, the Minister of Health and Social Welfare of Republika Srpska. Minister Seranic said that the medical professionals would be the priority group to receive the vaccine at a press conference, and 400,000 more Sputnik V doses are expected to arrive soon.

January 28, 2021 - Local media reported the first shipment of the Russian vaccine against Covid-19 "Sputnik V" will be received at Boufarik airport (wilaya of Blida), according to the Minister of Communication, spokesperson Ammar Belhimer. “The vaccination campaign will symbolically begin (Algeria) on Saturday from Blida in the presence of the Prime Minister, Abdelaziz Djerad,” added Mr. Belhimer, specifying that this operation will primarily concern medical staff, the elderly, and the chronically ill before 'being extended to the various categories of society.'

January 26, 2021 - The Moscow Times reported Russia's Foreign Minister Mohammad Javad Zarif announced Iran had approved the Sputnik V coronavirus vaccine. Iran has said it will only rely on vaccines made by Russia, India, or China while also producing a homemade jab.

January 24, 2021 - GAVI article: Coronavirus: why combining the Oxford vaccine with Russia's Sputnik V vaccine could make it more effective.

January 23, 2021 -  Reuters reported the Russian sovereign wealth fund announced it had signed an agreement with Turkey on its Sputnik V vaccine production.

January 21, 2021 - The Emirates News Agency reported the Ministry of Health and Prevention announced it had approved the Russian COVID-19 vaccine, Sputnik V, for emergency use, making it the third such vaccine to be approved for use in the UAE. The UAE has hosted the third phase of clinical trials of the vaccine, which was developed by the Gamaleya Research Institute of Epidemiology and Microbiology and the Ministry of Health of the Russian Federation. Study results have demonstrated the vaccine's effectiveness in triggering a strong antibody response against the virus, its safety for use, and its compliance with international safety and effectiveness standards.

January 21, 2021 - The Russian Direct Investment Fund announced the National Institute had approved the Sputnik V vaccine of Pharmacy and Nutrition of Hungary under the emergency use authorization procedure.  Thus Hungary has become the first country in the European Union to authorize Sputnik V's use.

January 19, 2021 - The Argentina National Administration communicated 'that, after analyzing the latest information provided for the VacunaGam-COVID-Vac (Sputnik V) vaccine, it was established, through the expansion report, that it is within an acceptable margin of safety, immunogenicity, and efficacy for the age group over 60 years. This information reported an efficacy range of 91.8% of the vaccine for those over 60 years of age; immunization of the volunteers led to the formation of antibodies in 98.1% on day 28 after vaccination, and the safety variable showed a profile that does not differ from that observed in the rest of the population. For all the above, considering that the safety, immunogenicity, and efficacy parameters are acceptable for those over 60 years of age, this National Administration recommended to the Ministry of Health of the Nation the use of the Vaccine Gam-COVID-Vac in the mentioned age group.

January 19, 2021 - According to local media, the Embassy of Russia in Mexico reported that Mexico would sign a contract for 12 million doses of the Russian SputnikV vaccine. This announcement was made known by the Secretary of Finance and Public Credit, Arturo Herrera.

January 19, 2020 - TASS reported Kazakhstan’s Health Minister Alexei Tsoi announced the country plans to start inoculating citizens with the Sputnik V vaccine on February 1st. The Sputnik V vaccine production was launched in Karaganda in late December 2020. It is planned to manufacture two million vaccine doses in stages.

January 18, 2021 - An Aerolíneas Argentinas flight picked up Argentina's second shipment of the Sputnik V coronavirus vaccine on January 15th at Sheremetyevo International Airport returned to Buenos Aires. The shipment of 300,000 doses of the world's first coronavirus vaccine follows a previous shipment of 300,000 doses shipped to Argentina on December 24. More than 200,000 people have been vaccinated in Argentina with the Sputnik V vaccine. Argentina is the first country in Latin America to authorize the Sputnik V vaccine.

January 15, 2021 - Hyderabad-based Dr. Reddy’s Laboratories Ltd. announced that it had received approval from the Drugs Control General of India to conduct a phase 3 clinical trial for the Sputnik V vaccine in India.

January 14, 2021 - Reuters reported Russia would submit a formal application to the European Union next month to approve its Sputnik V vaccine, which treats COVID-19.

January 13, 2021 - The Russian Direct Investment Fund announced the Sputnik V's registration by the Ministry of Health of the Bolivarian Republic of Venezuela. The supplies will be secured through RDIF's international partners in India, China, South Korea, and other countries.

January 13, 2021 - The Russian Direct Investment Fund and one of Brazil's leading pharmaceutical companies, União Química, have agreed to supply 10 million doses of the Sputnik V vaccine in the first quarter of 2021. The local production of Sputnik V has been launched in Brazil.

January 12, 2021 - TASS reported the Mexican Federal Commission for the Protection against Sanitary Risk might approve the emergency use of the "Sputnik V" COVID-19 vaccine this week, the country’s Deputy Minister of Health Hugo Lopez-Gatell.

January 11, 2021 - Reuters reported Mexico's Deputy Health Minister Hugo Lopez-Gatell said Mexico had reached agreements to acquire the Russian vaccine potentially. “We’re thinking that we could use up to 24 million doses of this vaccine, for 12 million people,” considering that Sputnik V vaccine requires two doses, Lopez-Gatell told a news conference.

January 11, 2021 - India - based Dr. Reddy’s Laboratories Ltd. announced that the independent Data and Safety Monitoring Board has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications. G V Prasad, Co-chairman and Managing Director, Dr. Reddy’s Laboratories, said in a press release, “The phase 2 study in India showed a very good safety profile. This further reinforces our confidence in Sputnik V's safety, which has now been administered to more than 1 million people in Russia and more than 300,000 people in Argentina. We are working closely towards fast-tracking the launch of the Sputnik V vaccine in India.”

January 11, 2021 - Moscow-based Russian Direct Investment Fund (RDIF) announced the Sputnik V vaccine registration against coronavirus by the Ministry of Health of Palestine. Sputnik V delivery to Palestine is planned for the first quarter of 2021, with the first batch expected to arrive within a month. Supplies of the vaccine will be facilitated by RDIF’s international partners in India, China, South Korea, and other countries.

January 11, 2021 - RT News reported, “Brazil will start production of Sputnik V on January 15, 2021." The Russian vaccine will be manufactured by the Brazilian pharmaceutical company União Química at two plants, one in Brasilia and Guarulhos. The firm has already received the cellular material to produce the vaccine from its developer, Moscow’s Gamaleya Institute.

January 10, 2021  - The Russian Direct Investment Fund (RDIF) announces the Sputnik V vaccine registration by the National Pharmaceutical Agency of the People's Democratic Republic of Algeria, which became the first African state to approve vaccines officially. Vaccine supplies to Algeria will be ensured through RDIF's international partners in India, China, South Korea, and other countries.

January 8, 2021 - A New York Times reporter juggled fears engendered by the Sputnik V vaccine's politicized rollout with the urge to gain protection from the deadly virus.

January 8, 2021 - Bloomberg article: Sputnik V has one key, clever difference from the Astra and J&J vaccines: It uses the same adenovirus as J&J for the first dose (adenovirus-26) and a different adenovirus (adenovirus-5) for the second dose. In this way, it avoids the possibility of immunity to the first dose impacting the second dose's ability to work efficiently. One issue is that a large percentage of people have pre-existing immunity to adenovirus-5, but that’s not a huge drawback if the efficacy is very high.

January 6, 2021 - The Russian Direct Investment Fund and the Government of Serbia announce an agreement to supply the country with 2 million doses of Sputnik V vaccine. The first batch of the vaccine was delivered to Serbia on December 30, 2020. The vaccine was approved without additional clinical trials in the country.

January 6, 2021 - The Russian Direct Investment Fund announced the Sputnik V vaccine registration by the State Agency for Medicines and Health Technologies (Agencia Estatal De Medicamentos Y Tecnologías En Salud, AGEMED) of the Plurinational State of Bolivia.

January 6, 2021 - Ukrainian pharmaceutical firm Biolik said in a statement on its website it had applied to register Gam-COVID-Vac, also known as Sputnik V, in Ukraine.

January 2, 2021 - Russia's Minister of Health Mikhail Murashko told reporters on Saturday. "Taking into account all data, more than 800,000 people have been vaccinated," he said. Murashko stressed that vaccination is in progress among Russian citizens over 60 years old, reported TASS.

December 31, 2020 - Algeria announced it would use the Russian Sputnik V coronavirus vaccine for mass vaccinations for its population scheduled for January 2021, TSA news portal reports, citing the decision made by the Algerian government following a meeting on Wednesday chaired by Prime Minister Abdelaziz Djerad.

December 29, 2020 - The Ministry of Health of the Republic of Belarus, the Ministry of Health of the Russian Federation, and the Russian Direct Investment Fund announced the start of vaccination of Belarus's population with the Sputnik V Russian vaccine against coronavirus. Belarus became the first state after Russia to officially register Sputnik V.

December 29, 2020 - Argentina became the third country worldwide to begin vaccinations with the Sputnik V vaccine outside of clinical studies.

December 29, 2020 - Turkey's health officials announced plans to produce the Sputnik V vaccine domestically.

December 28, 2020 - Hungary's Foreign Minister Peter Szijjarto posted on his Facebook page 'the country has received 6,000 doses of Russia's COVID-19 vaccine.' reported Reuters.

December 26, 2020 - Russian Health Minister Mikhail Murashko announced on the Russia-24 broadcaster that the use of the Sputnik V coronavirus vaccine had been approved for people aged 60 and older. "The Health Ministry approved amendments to the instructions for medical use [of the vaccine]. Thus, citizens over 60 years old can now be vaccinated against the new coronavirus infection."

December 21, 2020 - The Russian Direct Investment Fund announced a marketing authorization for the Sputnik V vaccine by the Ministry of Health of the Republic of Belarus. Thus, Belarus became the first foreign state to register a vaccine on its territory officially. Vaccination of volunteers in the Republic of Belarus began on October 1, 2020. As part of a double-blind, randomized, placebo-controlled clinical trial, the Sputnik V vaccine involved 100 people in eight medical institutions selected as research centers.

December 21, 2020 - Russian Direct Investment Fund, N.N. N.F. Gamaleas and the pharmaceutical companies AstraZeneca and R-Pharm announced the signing of an agreement on developing and implementing a clinical research program to assess the immunogenicity and safety of the combined use of one of the components of the Sputnik V vaccine of the Center. The parties also agreed to develop scientific and business relations within the framework of the possibilities of joint use of the Sputnik V vaccine. The AZD1222 vaccine will be studied to more persistent and long-term immunization of a person against a new coronavirus infection. A clinical study of the combination of the AZD1222 vaccine with the adenoviral vector of the Sputnik V vaccine of the 26th serotype will begin shortly. The R-Pharm company will also co-sponsor the study.

December 21, 2020 - The Russian Direct Investment Fund announces the start of production of the world's first registered vaccine against coronavirus Sputnik V in the Republic of Kazakhstan. The vaccine's validation batch has been released today by the Karaganda pharmaceutical complex. The batch will be sent to the developer of the vaccine - NITsEM them. N.F. Gamalei. Karaganda Pharmaceutical Complex is an innovative biotechnological pharmaceutical enterprise with a full range of necessary equipment, qualified personnel, and international standards.

December 15, 2020 - Presented by the Orthodox Union and the Rabbinical Council of America: the conclusion of our poskim is that, pursuant to the advice of your personal health care provider, the Torah obligation to preserve our lives and the lives of others requires us to vaccinate for COVID-19 as soon as a vaccine becomes available.

December 14, 2020 - According to the Protocol of Phase III clinical trials of the Sputnik V vaccine, its intermediate efficacy is calculated at three statistically significant representative control points - upon reaching 20, 39, and 78 cases of new coronavirus infection among subjects in both the placebo group and in the group that received the vaccine. As a result of the Data analysis at the first checkpoint (20 cases of the disease), the estimated vaccine efficiency was 92%, at the second checkpoint (39 cases of the disease) - 91.4%. Based on the data obtained to date from the N.I. N.F. Gamalei will prepare a report used to submit documents for the accelerated registration of the Sputnik V vaccine in various countries.

December 11, 2020 - After receiving results on the Russian vaccine's high efficiency "Sputnik V," the Russian Direct Investment Fund, and the N.F. Gamaleya Research Center, on November 23, 2020, made a proposal to AstraZeneca on the use of 1 of the 2 components (human adenoviral vectors) of the Russian Sputnik V vaccine in clinical trials of the AstraZeneca vaccine. AstraZeneca has accepted the RDIF proposal and will begin clinical trials of its vaccine combined with the Sputnik V adenoviral vector of the 26th serotype by the end of 2020.

December 10, 2020 - The Russian Direct Investment Fund and the Government of Argentina have agreed to supply 10 million doses of Sputnik V vaccine to the country.

December 8, 2020 - Russian organizations announced the cosmonaut squad of the V.I. Yu.A. Gagarin and the Cosmonaut Training Center staff interacting with them would be vaccinated. In the future, other employees of the Center and key enterprises of the State Corporation Roscosmos will have the opportunity to protect themselves from SARS-CoV-2 coronavirus infection.

December 8, 2020 - The Director-General of the Russian Direct Investment Fund Kirill Dmitriev, Director of the N.N. N.F. Gamalei Alexander Gintsburg and the head of the Opposition Platform's political council - For Life party, deputy of the Verkhovna Rada of Ukraine Viktor Medvedchuk held a meeting, during which they discussed the possibility of technological transfer and launch of production in Ukraine of the Sputnik V vaccine.

December 4, 2020 - The Russian Direct Investment Fund and the Ministry of Health of the Republic of Kazakhstan announced a cooperation agreement for the registration procedure and the Sputnik V vaccine production and distribution. After receiving Kazakhstan's regulatory authorities' approval, technology transfer will be carried out. The substance's supply to produce at least 2 million doses of the Sputnik V vaccine in the country.

December 4, 2020 - The Russian Federation's capital city of Moscow's mayor reported 'in the first five hours, 5,000 people signed up for the vaccination - teachers, doctors, social workers, those who today most of all risk their health and lives.'

December 2, 2020 - Russian Health Minister Mikhail Murashko said more than 100,000 people had already been vaccinated against COVID-19, as Moscow presented its Sputnik V vaccine to the United Nations over a video link.

December 1, 2020 - Dr. Reddy’s Laboratories Ltd., based in Hyderabad, and the Russian Direct Investment Fund announced they had commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drugs Laboratory, Kasauli, India. This will be a multicenter and randomized controlled study, including a safety and immunogenicity study. G V Prasad, Co-chairman and Managing Director, Dr. Reddy’s Laboratories said in a press release: “We are working towards making the vaccine available with a combination of import and indigenous production model.”

November 27, 2020 - HYDERABAD-based Hetero Labs has joined RDIF to manufacture over 100 million doses of the Sputnik V vaccine in India during 2021.

November 24, 2020 - Article published by Science.org: 'The developers of Russia’s Sputnik V vaccine today reported 91.4% efficacy from a second interim analysis of more than 18,000 people, bolstering a claim the team made on 11 November with scant evidence. Whereas the initial report rested on a mere 20 cases of COVID-19, with no details on how they were split between vaccinated and placebo groups, the new analysis is based on 39 cases total, eight among the vaccinated group versus 31 in the much smaller placebo arm.'

November 24, 2020 - N.N. N.F. The Gamaleis of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund announced the positive results of the second interim analysis of Phase III data of the largest double-blind, randomized placebo-controlled clinical post-marketing clinical trial of the Sputnik V coronavirus vaccine in Russian history with the participation of 40,000 volunteers.

November 17, 2020 - The Russian Direct Investment Fund announced a survey of more than 12 thousand respondents in 11 countries about their attitude to vaccination against coronavirus infection. According to the survey, 73% of respondents are ready to be vaccinated against coronavirus.

November 13, 2020 - The Russian Direct Investment Fund and GL Rapha, one of South Korea's leading biotechnology companies, announced an agreement to manufacture in the country more than 150 million doses of the world's first registered vaccine against coronavirus Sputnik V. The parties intend to start production in December of this year and begin deliveries of the vaccine for export in January 2021. More than 150 million doses of the Sputnik V vaccine produced in South Korea will enter the world market.

November 12, 2020 - Hungary's foreign affairs and trade minister Peter Szijjarto announced on national TV that Budapest would receive a Sputnik V sample within a week-and-a-half for laboratory testing. Clinical trials and licensing begin in December 2020, and depending on the results, Hungary will begin to procure the vaccine in January 2021.

November 11, 2020 - Reuters reported Russia’s Sputnik V vaccine is 92% effective at protecting people from COVID-19. 'The uniqueness of the Russian vaccine lies in the use of two different vectors based on the human adenovirus, which allows for a stronger and longer-term immune response as a result of the second immunization.' Alexander Gintsburg, director of the Gamaleya Institute, which developed the vaccine, said the interim results demonstrated that Sputnik V was effective. Vaccinations would be rolled out in Russia in the coming weeks.

November 9, 2020 - The Russian Direct Investment Fund and the N.F. The Gamaleis announced an international social media campaign that will provide social media users with the latest and most reliable Russian vaccine information. The campaign uses the #SputnikV hashtag.

October 30, 2020 - Russian Direct Investment Fund, União Química Farmacêutica Nacional, and the Government of Parana's State announce the preliminary submission of a set of documents for a Russian registration vaccine to the Brazilian National Sanitary Inspection Agency. The documents were sent to October 29, 2020.

October 29, 2020 - Dr. Reddy’s Laboratories announced its partnership with the Biotechnology Industry Research Assistance Council, Department of Biotechnology, Government of India, for advisory support on the Sputnik V vaccine's clinical trials in India.

October 27, 2020 - Russian application for WHO prequalification of the Sputnik V vaccine was first since the start of applications.

October 26, 2020 - About 19,000 people have been administered the first component of the Sputnik V vaccine in Moscow and the Moscow Region, about 6,500 of whom have already received the second component, Director of the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry that developed the vaccine, Alexander Gintsburg said in an interview with the Russia-24 TV channel. The vaccination against coronavirus infection with the Russian drug Sputnik V is tolerated without side effects by 85% of those vaccinated.

October 17, 2020 - Russian Direct Investment Fund and Dr. Reddy's Laboratories Ltd (Dr. Reddy's), one of the leading global pharmaceutical companies, has been approved by the Controller General of Medicines of India to conduct Phase 2-3 clinical trials of Sputnik V vaccine in India. The country will conduct multicenter, randomized controlled trials, including safety and immunogenicity trials.

October 14, 2020 - According to a statement: '13,000 of our citizens, volunteers, are already participating in them, and, as you know, the vaccine has already arrived in the constituent entities of the Russian Federation, albeit not in large quantities, but it has already arrived.'

October 12, 2020 - The Russian Direct Investment Fund (RDIF) announced the approval by the Ministry of Health and Prevention of the UAE to conduct Phase III clinical trials of the Sputnik V vaccine. The clinical trials will be overseen by the Abu Dhabi Department of Health and the UAE Ministry of Health and Prevention. The Abu Dhabi Health Services Company, a state-owned Abu Dhabi hospital management company, will process medical protocols.

October 2, 2020 - In a video posted on YouTube, the Russian Federation's capital city of Moscow stated: 'Moscow could receive bulk shipments of Russia’s coronavirus vaccine by the end of 2020 while the vaccine continues to undergo final clinical trials. Around 6,000 volunteers and 600 medics have been inoculated with the Sputnik V vaccine in the Russian capital as part of post-registration, double-blind trials.

October 2, 2020 - The Russian Direct Investment Fund announced the Sputnik V vaccine's first batch to Venezuela's Bolivarian Republic. Vaccination of volunteers in Venezuela will begin in the coming days as part of double-blind, randomized, placebo-controlled clinical trials of the Sputnik V vaccine.

October 1, 2020 - The Lancet published an article: Sputnik V's arrival.

September 30, 2020 - The Russian Direct Investment Fund and Pharco, one of the leading pharmaceutical groups in Egypt (acting through its key operational subsidiary – Biogeneric Pharma), have agreed to secure the supply of 25 million doses of the Sputnik V vaccine to Egypt. 

September 29, 2020 - The Russian Direct Investment Fund and one of the leading pharmaceutical distributors in Nepal, Trinity Pharmaceuticals, have agreed to supply 25 million doses of the Sputnik V vaccine based on a well-studied human adenoviral vectors platform.

September 25, 2020 - The Russian Direct Investment Fund said it is in talks with several countries, including Iran, about the possibility of locally producing the Sputnik-V vaccine to reduce the number of coronavirus infections.

September 22, 2020 - The Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry said it is developing a coronavirus vaccine study protocol for cancer patients.

September 18, 2020 - The Lancet published 'Safety and efficacy of the Russian COVID-19 vaccine: more information needed,' and the related reply.

September 16, 2020 - The Russian Direct Investment Fund and Dr. Reddy’s Laboratories Ltd. have agreed to cooperate on clinical trials and distribute the Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply Dr. Reddy’s 100 million vaccine doses. Deliveries could begin in late 2020, subject to completion of successful trials and registration of the vaccine by India's regulatory authorities.

September 16, 2020 - The Russian Direct Investment Fund announced discussions with the Republic of Korea on the possibility of production of the Russian Sputnik V vaccine. The negotiations are at their final stage.

September 15, 2020 - Researchers highlight ‘questionable’ data in Russian coronavirus vaccine trial results.

September 11, 2020 - The Russian Direct Investment Fund and the Health Secretariat of the Brazilian state of Bahia signed a cooperation agreement to supply Brazil with up to 50 million doses of the Russian Sputnik V vaccine, beginning in November 2020, subject to Brazilian government regulatory approval. The agreement will also allow the vaccine to be shipped throughout Brazil in the future.

September 9, 2020 - The Russian Direct Investment Fund and the Landsteiner Scientific pharmaceutical company announced an agreement for the supply of 32 million doses of the Russian Sputnik V vaccine to Mexico's country.

September 7, 2020 - Russia's Health Ministry Mikhail Murashko stated, 'The first batch of Sputnik V vaccine has been produced for civilian circulation,' reported the Tass news agency. Previously, Minister Murashko explained that civilian production at this stage 'meant vaccination of citizens from the risk groups, namely teachers and doctors, would be carried out simultaneously with post-registration clinical trials.'

September 4, 2020 - The Lancet study: Safety and immunogenicity of a rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomized phase 1/2 studies from Russia.

September 4, 2020 - The technology institute for the Brazilian state of Paraná has agreed to produce Russia’s “Sputnik-V” COVID-19 vaccine, said on Friday it plans to conduct phase III trials on 10,000 volunteers in Brazil at the start of 2021.

September 2, 2020 - Employees of the National Research Center for Epidemiology and Microbiology were vaccinated against COVID-19, the director of the institution, Alexander Ginsburg, told RIA Novosti. According to Gunzburg, the participants in this stage will be closely monitored by doctors, and they will not be hospitalized. Still, they will take all the necessary tests before, after, and during the research.

August 26, 2020 - The Russian Direct Investment Fund, the Government of Moscow, and the Gamaleya National Research Center of Epidemiology and Microbiology announce the start of a post-registration clinical trial of a coronavirus vaccine in Moscow. Forty thousand people will take part in the program.

August 16, 2020 - Sputnik V's developer said the 3rd stage of trials could be called mass vaccination. The tests will be carried out in the Moscow Region, and some 20,000 - 30,000 people will get the vaccine.

August 15, 2020 - Russia announced that it had produced its first batch coronavirus vaccine.

August 11, 2020 - The Russian Federation's President Putin said his daughter was inoculated with a new Russian coronavirus vaccine.

August 11, 2020 - OP-ED: THE SPUTNIK VACCINE AS A LIFESAVING GLOBAL PARTNERSHIP.

August 8, 2020 - Special video report on the Russian vaccine against COVID-19 07.08.2020, Russia-24.

August 6, 2020 - Russia is planning a mass vaccination campaign in October, and the vaccine will be first given to doctors and teachers.

August 4, 2020 - Video interview of RDIF CEO Kirill Dmitriev with the BBC.

August 1, 2020 - Clinical trials of a coronavirus vaccine developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology are over, Russian Health Minister Mikhail Murashko told reporters.

July 19, 2020 - "Russia may be one of the first to produce a vaccine against the backdrop of the billions that are being invested by all the pharma companies working on it,” said Kirill Dmitriev, the chief executive of the Russian Direct Investment Fund, which previously signed a deal with AstraZeneca to manufacture the University of Oxford’s Covid-19 vaccine at R-Pharm, one of the largest pharmaceutical companies in Russia. 

July 16, 2020 - Russia plans to produce 30 million doses of an experimental COVID-19 vaccine domestically this year. With the potential to manufacture a further 170 million abroad, its sovereign wealth fund's head told Reuters.

July 13, 2020 - The Gamalei center's head Alexander Gintsburg told the TASS news agency that he hopes the vaccine will “enter civil circulation” on Aug. 12-14. He added that he hopes private companies would begin mass production by September. “The research has been completed, and it proved that the vaccine is safe,” Yelena Smolyarchuk, the head of Sechenov University’s clinical research center, told TASS of its trial.

July 12, 2020 - Russia's Sechenov University Announced Successfully Completing Clinical Trials of World's 1st COVID-19 Vaccine. Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical, and Vector-Borne Diseases at Sechenov University, said that this stage of the clinical study's objective was to show the vaccine’s safety for human health, which was successfully done.

July 10, 2020 - The Russian Ministry of Defense announced that it started the final stage of the Coronavirus vaccine clinical trials, run by the Gamalei National Research Center for Epidemiology and Microbiology. These trials began on June 18th, when nine volunteers received 1 component of the vaccine. On June 23th, the vaccine was given to 20 other volunteers who will receive the booster vaccination.

July 7, 2020 - Volunteers who tested a vaccine against the coronavirus  2 weeks ago at Burdenko military hospital feel well and have not experienced any side effects, the Russian Defense Ministry told reporters.

June 11, 2020 - Hit Hard by Coronavirus, Russia Joins Global Race for a Vaccine.

June 10, 2020 - RDIF has supported developing a Russian COVID-19 vaccine scheduled to commence clinical trials by mid-June 2020 and enter production by the fall.

June 4, 2020 - Russia plans to start clinical testing of a coronavirus vaccine on paid volunteers from the general public.

May 29, 2020 - Alexander Gintsburg of Moscow's Gamaleya research institute said last week he had taken a dose of a so-called viral vector vaccine that he hopes will complete clinical trials by the end of the summer.

May 22, 2020 - Russian developers of a coronavirus vaccine have developed immunity to the infection after self-administering it.

Sputnik V Vaccine Clinical Trials

A list of relevant clinical studies is published by Sputnik V vaccine.

Clinical Trial NCT04530396: Phase 3 Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 (RESIST). Randomized, double-blind (blinded for the trial subject and the study physician), placebo-controlled, multi-center clinical trial in the parallel assignment of efficacy, immunogenicity, and safety Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults in the SARS-СoV-2 infection prophylactic treatment.

Clinical Trial NCT04436471 - An open two-stage non-randomized Phase 1/2 study with 38 healthy volunteers. This clinical trial is an open study of the safety, tolerability, and immunogenicity of the drug "Gam-COVID-Vac" solution for intramuscular administration, with healthy volunteers' participation.